Overview

Allo HSCT for High Risk Hemoglobinopathies

Status:
RECRUITING

Trial end date:
2032-06-01

Target enrollment:

Participant gender:

Summary

A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

Phase:

PHASE2

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Treatments:

Alemtuzumab
Busulfan
Cyclophosphamide
fludarabine
Insulin Infusion Systems
Mesna
Mycophenolic Acid
Sirolimus
Tacrolimus
Thiotepa
thymoglobulin
Whole-Body Irradiation